Edwards Lifesciences Pre-Tax Profit Margin 2010-2022 | EW

Current and historical pre-tax profit margin for Edwards Lifesciences (EW) from 2010 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Edwards Lifesciences pre-tax profit margin for the three months ending December 31, 2022 was .
Edwards Lifesciences Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2022-12-31 $5.38B $1.77B 32.83%
2022-09-30 $5.36B $1.68B 31.39%
2022-06-30 $5.36B $1.67B 31.15%
2022-03-31 $5.36B $1.75B 32.65%
2021-12-31 $5.23B $1.70B 32.52%
2021-09-30 $5.10B $1.68B 33.01%
2021-06-30 $4.93B $1.66B 33.60%
2021-03-31 $4.48B $0.94B 21.03%
2020-12-31 $4.39B $0.92B 20.90%
2020-09-30 $4.37B $0.88B 20.07%
2020-06-30 $4.32B $0.82B 18.86%
2020-03-31 $4.48B $1.25B 27.97%
2019-12-31 $4.35B $1.17B 26.84%
2019-09-30 $4.15B $0.85B 20.45%
2019-06-30 $3.97B $0.80B 20.08%
2019-03-31 $3.82B $0.78B 20.30%
2018-12-31 $3.72B $0.76B 20.46%
2018-09-30 $3.64B $1.09B 29.93%
2018-06-30 $3.55B $1.05B 29.61%
2018-03-31 $3.45B $1.01B 29.18%
2017-12-31 $3.44B $1.04B 30.14%
2017-09-30 $3.32B $0.91B 27.50%
2017-06-30 $3.23B $0.89B 27.37%
2017-03-31 $3.15B $0.85B 26.92%
2016-12-31 $2.96B $0.74B 24.87%
2016-09-30 $2.87B $0.70B 24.56%
2016-06-30 $2.74B $0.67B 24.43%
2016-03-31 $2.60B $0.64B 24.72%
2015-12-31 $2.49B $0.62B 24.98%
2015-09-30 $2.44B $0.59B 24.13%
2015-06-30 $2.43B $0.56B 22.99%
2015-03-31 $2.39B $1.23B 51.46%
2014-12-31 $2.32B $1.14B 49.27%
2014-09-30 $2.24B $1.11B 49.60%
2014-06-30 $2.13B $1.09B 51.20%
2014-03-31 $2.07B $0.40B 19.22%
2013-12-31 $2.05B $0.51B 25.02%
2013-09-30 $2.02B $0.53B 26.29%
2013-06-30 $1.97B $0.52B 26.57%
2013-03-31 $1.94B $0.49B 25.45%
2012-12-31 $1.90B $0.39B 20.43%
2012-09-30 $1.82B $0.34B 18.58%
2012-06-30 $1.78B $0.30B 16.98%
2012-03-31 $1.73B $0.29B 16.50%
2011-12-31 $1.68B $0.29B 16.97%
2011-09-30 $1.64B $0.29B 17.43%
2011-06-30 $1.58B $0.29B 18.64%
2011-03-31 $1.51B $0.29B 18.99%
2010-12-31 $1.45B $0.27B 18.52%
2010-09-30 $1.40B $0.26B 18.54%
2010-06-30 $1.38B $0.29B 20.88%
2010-03-31 $1.35B $0.29B 21.11%
2009-12-31 $1.32B $0.30B 22.98%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $50.772B $5.382B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $230.517B 25.29
Alcon (ALC) Switzerland $37.369B 32.17
STERIS (STE) Ireland $21.864B 27.21
Teleflex (TFX) United States $12.124B 19.67
Fresenius Medical Care AG KGaA (FMS) Germany $11.123B 11.16
Penumbra (PEN) United States $9.913B 2372.91
Globus Medical (GMED) United States $7.950B 40.42
Glaukos (GKOS) United States $2.458B 0.00
Integer Holdings (ITGR) United States $2.435B 19.55
AVANOS MEDICAL, INC (AVNS) United States $1.469B 20.92
Nevro (NVRO) United States $1.410B 0.00
Paragon 28 (FNA) United States $1.346B 0.00
Artivion (AORT) United States $0.566B 0.00